Project Details
Description
A Multi-Center Randomized Double Blind Placebo-Controlled Phase III trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Theraapy following Allogeneic Transplant for patients with FLT3-ITD AML
| Status | Active |
|---|---|
| Effective start/end date | 5/1/17 → 7/31/24 |
Funding
- NATIONAL MARROW DONOR PROGRAM
- ASTELLAS PHARMA US, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.